Companies in the News

eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Stu

SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The results of the research, led by Nevan Krogan, Ph.D., professor, department of cellular and molecular pharmacology and director of the Quantitative Bioscience Institute at UCSF, were reported today in the peer-reviewed journal Nature, in a manuscript titled “A SARS-CoV-2 Protein Interaction Map Reveals Host Targets for Drug-Repurposing” by David E. Gordon et al. Currently being tested in patients w

eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Rece

Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of Oncogene Drivers SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced that data presented today in a virtual session at the AACR Annual Meeting, showed the anti-tumor activity of the company’s product candidate, zotatifin, in preclinical models of FGFR1, FGFR2 and HER2 driven cancers, demonstrating the potential of zotatifin in receptor tyrosine kinase (RTK)-driven cancers. Peggy A. Thompson, Ph.D., executive director, t

GlaxoSmithKline injects US$250mln into US biotech Vir in coronavirus treatment collaboration

Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays GlaxoSmithKline PLC (LON:GSK) is to invest US$250mln into Nasdaq-listed Vir Biotechnology Inc (NASDAQ:VIR), with the two companies to work together on potential treatments for coronavirus. It is the pharma major and vaccine specialist’s first announcement specifically about the virus since the outbreak. The collaboration will use Vir's platform technology to identify new anti-viral antibodies for therapies while Glaxo will screening for anti-coronavirus compounds and research into SARS-CoV-2 and other linked vaccines. The initial focus will be on two promising candidates already i